In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses

Anti-Cancer Drugs

Volumn 12, Issue 1, 2001, Pages 71-78

  Arencibia, J M ^a   Schally, A V ^a   Halmos, G ^a   Nagy, A ^a   Kiaris, H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytotoxic LHRH analog; LHRH receptor; Ovarian cancer; Targeted cancer therapy

Indexed keywords

2 PYRROLINODOXORUBICIN; DOXORUBICIN; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; MEMBRANE PROTEIN;

ADULT; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CASE REPORT; CELL CULTURE; CELL KINETICS; CELL SELECTION; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TARGET CELL;

ANTINEOPLASTIC AGENTS; COCULTURE TECHNIQUES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICROSATELLITE REPEATS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, LHRH; TOXICITY TESTS; TUMOR CELLS, CULTURED;

EID: 0035129338     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200101000-00010     Document Type: Article

References (31)

1. LH-RH analogues: Their impact on human reproduction and on the control of tumorigenesis
2. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
3. Chemotherapy targeted to hormone receptors on tumors
4. 6] luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer
5. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
6. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone
7. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers
8. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
9. Targeting of cytotoxic bombesin analog AN-215 to H-69 small cell lung carcinoma as demonstrate by semi-quantitative microsatellite analysis in vitro
10. Quantitation of the allelic imbalance provides evidence on tumor heterogeneity: A hypothesis
11. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies
12. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin
13. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice
14. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75)
15. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers
16. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LHRH) in rats by LHRH antagonist Cetrorelix
17. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
18. A versatile computerized approach for characterization of ligand binding systems
19. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line
20. Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer
21. The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines
22. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor on rat and human prostate cancers and in benign prostate hyperplasia
23. Presence of gonadotropin releasing hormone and his messenger ribonucleic acid in human ovarian epithelial carcinoma
24. 6]luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer
25. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata
26. 6]-LH-RH and EGF in human endometrial carcinoma
27. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancer in nude mice
28. Regulation of targeted chemotherapy with cytotoxic luteinizing hormone-releasing hormone analogue by epidermal growth factor
29. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238
30. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone